Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3029
Hope S. Rugo ₁ , Sara M. Tolaney ₂ , Aditya Bardia ₃ , Javier Cortes ₄ , Frederik Marmé ₅ , Peter Schmid ₆ , Lisa A. Carey ₇ , Sibylle Loibl ₈ , Kevin Kalinsky ₉ , Joyce O'Shaughnessy ₁₀ , Sara A. Hurvitz ₁₁ , Theresa Valdez ₁₂ , Ya Meng ₁₂ , Wendy Verret ₁₂ , Scott T. Tagawa ₁₃

Affiliation

University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, CA
International Breast Cancer Center, Quironsalud Group, Barcelona, Spain and Universidad Europea de Madrid, Madrid, Spain
Universitätsmedizin Mannheim, Heidelberg, Germany
Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany
Winship Cancer Institute of Emory University, Atlanta, GA
Baylor University Medical Center, Texas Oncology, The US Oncology Network, Dallas, TX
Fred Hutchinson Cancer Center and University of Washington Medicine, Seattle, WA
Gilead Sciences, Inc, Foster City, CA
Weill Cornell Medicine, New York, NY